Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $102,712 | $59,162 | $35,640 | $46,057 |
| - Cash | $10,355 | $11,628 | $13,280 | $14,998 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $92,357 | $47,535 | $22,360 | $31,059 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,141 | -$2,127 | -$1,431 | -$2,403 |
| % Margin | – | – | – | – |
| Net Income | -$2,158 | -$2,145 | -$1,676 | -$2,463 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.05 | -0.052 | -0.061 | -0.09 |
| % Growth | 4.2% | 14.6% | 32% | – |
| Operating Cash Flow | -$1,273 | -$1,652 | -$1,602 | -$1,406 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,273 | -$1,652 | -$1,602 | -$1,406 |